Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15744178 | 1.00 | CYP4F2 (0.39) | CYP4F2CYP4A11ALDH1A1MAPTLMNA | |
| SCHEMBL25392984 | 0.90 | CYP4F2 (0.39) | CYP4F2CYP4A11ALDH1A1MAPTLMNA | |
| SCHEMBL30182911 | 0.87 | MAPT (0.38) | CYP4F2CYP4A11ALDH1A1MAPTLMNA | |
| SCHEMBL18295841 | 0.85 | CYP4F2 (0.39) | CYP4F2CYP4A11ALDH1A1MAPTLMNA | |
| SCHEMBL21198696 | 0.85 | CYP4F2 (0.39) | CYP4F2CYP4A11ALDH1A1MAPTLMNA | |
| SCHEMBL9904367 | 0.85 | MAPT (0.37) | CYP4F2CYP4A11ALDH1A1MAPTLMNA | |
| SCHEMBL24268653 | 0.85 | MAPT (0.37) | CYP4F2CYP4A11ALDH1A1MAPTLMNA | |
| SCHEMBL18281904 | 0.85 | GAA (0.41) | CYP4F2CYP4A11ALDH1A1MAPTLMNA | |
| SCHEMBL20163477 | 0.85 | CYP4F2 (0.39) | CYP4F2CYP4A11ALDH1A1MAPTLMNA | |
| SCHEMBL30615352 | 0.85 | MAPT (0.37) | CYP4F2CYP4A11ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240830-B2 | Fused ring heteroaryl compounds and use thereof | BISICHEM CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| EP-4384511-A1 | FUSED RING HETEROARYL COMPOUNDS AND USE THEREOF | Bisichem Co., Ltd. (KR) | 2024-06-19 | — | — | EP | disclosed |
| EP-4377306-A1 | ROCK2 INHIBITORS AND USES THEREOF | President and Fellows of Harvard College (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-118055926-A | ROCK2 inhibitors and uses thereof | 哈佛大学的校长及成员们 | 2024-05-17 | — | — | CN | disclosed |
| CN-117881669-A | Condensed ring heteroaryl compounds and uses thereof | 比西切姆有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117529476-A | Preparation of substituted 1, 2-diamino heterocyclic derivatives and their use as medicaments | 亚飞络思制药公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3544967-B1 | SALTS OF INDAZOLE DERIVATIVE AND CRYSTALS THEREOF | EISAI R&D MAN CO LTD (JP) | 2023-06-28 | — | — | EP | disclosed |
| US-20230089180-A1 | FUSED RING HETEROARYL COMPOUNDS AND USE THEREOF | BISICHEM CO., LTD. (KR) | 2023-03-23 | — | — | US | disclosed |
| US-8299112-B2 | Estrogen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299112-B2 | Estrogen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299112-B2 | Estrogen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| WO-2012037411-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012037410-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012037410-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037411-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089180-A1 | FUSED RING HETEROARYL COMPOUNDS AND USE THEREOF | ALK, CYP3A5, SMAD3 | CYP4F2 164/4885CYP4A11 42/4885ALDH1A1 727/4885 |
| US-12240830-B2 | Fused ring heteroaryl compounds and use thereof | ALK, CYP3A5, SMAD3 | CYP4F2 164/4885CYP4A11 42/4885ALDH1A1 727/4885 |
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | CYP4F2 604/4885CYP4A11 131/4885ALDH1A1 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.